Freitag, 6. August 2021
Navigation öffnen

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy



Mai 2020

Letztes Update:

Durvalumab Injection [Imfinzi]

Indikation (Clinical Trials):
Carcinoma, Non-Small-Cell Lung


Erwachsene (18+)

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Thoraxklinik-Heidelberg gGmbH, AstraZeneca,


Farastuk Bozorgmehr, Dr. med.
Principal Investigator
Dept. of Thoracic Oncology Thoraxklinik at Heidelberg University


Farastuk Bozorgmehr, Dr. med.
Phone: +49 6221-396 8077
» Kontaktdaten anzeigen

(3 von 7)

Thoraxklinik am Universitätsklinikum Heidelberg
69126 Heidelberg
GermanyRekrutierend» Google-Maps
Farastuk Bozorgmehr, Dr.
Phone: +49 6221 396
Phone (ext.): 8807
» Ansprechpartner anzeigen
Lungenklinik Hemer, Pneumologie und Thorakale Onkologie
58675 Hemer
GermanyRekrutierend» Google-Maps
Alle anzeigen


Detailed Description:

This trial investigates the feasibility and treatment efficacy when combining durvalumab treatment with either conventionally fractionated (CON-group) or hypofractionated thoracic radiotherapy (HYPO-group) in previously untreated NSCLC stage III patients prone to radiotherapy only.

A safety lead-in phase with stop-and-go design will precede full enrollment into the HYPO-group.

Tumor tissue as well as blood and stool samples will be collected for future biomarker analysis.

It is hypothesized that TRT combined with concurrent durvalumab administration in patients with unresectable stage III NSCLC, who are not amenable to sequential radio-/chemotherapy

1. is safe and feasible,

2. will improve treatment efficacy by a synergistic effect of checkpoint inhibition and the photon-induction of immunostimulatory pathways.

3. will have an effect on the immunological characteristics of the tumor, the microenvironment, and the systemic immune response, such as upregulation of PD-L1 or secretion of stimulatory cytokines and recruitment and priming of immunocompetent cells, which might then mediate the "abscopal effect" beyond the irradiated targets.


Inclusion Criteria:

1. Fully-informed written consent and locally required authorization (European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.

2. Age ≥ 18 years.

3. Histologically documented diagnosis of unresectable stage III NSCLC.

4. Non-feasibility of sequential chemo-/radiotherapy as determined by the site's multi-disciplinary tumor board; if there is no tumor board, then this decision will be made by the investigator in consultation with a radiation oncologist, if the investigator is not a radiation oncologist; or by the investigator in consultation with an oncologist, if the investigator is not an oncologist.

5. Fulfills at least one of the following criteria:

- Performance status (PS) 2 (ECOG scale)

- ECOG 1 and CCI ≥ 1

- Age ≥ 70 years

6. Must have a life expectancy of at least 12 weeks.

7. FEV1 ≥ 40%

8. DLCO ≥ 40%

9. FVC or VC ≥ 70%

10. At least one measurable site of disease as defined by RECIST 1.1

11. Adequate bone marrow and renal function including the following:

- Hemoglobin ≥ 9.0 g/dL;

- absolute neutrophil count ≥ 1.0 x 103/L;

- platelets ≥75x 109/L;

- Calculated creatinine clearance ≥30 mL/min as determined by the Cockcroft-Gault equation

12. Adequate hepatic function (with stenting for any obstruction, if required) including the following:

- Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN);

- AST (SGOT) / ALT (SGPT) ≤ 2.5x institutional ULN

13. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.

14. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.

15. The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.

Exclusion Criteria:

1. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study.

2. Participation in another clinical study with an investigational product within 21 days prior to the first dose of the study treatment.

3. Prior immunotherapy or use of other investigational agents, including prior treatment with an anti-Programmed Death receptor-1 (PD-1),anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T-lymphocyte associated antigen-4 (anti-CTLA-4) antibody, therapeutic cancer vaccines.

4. History or current radiology suggestive of interstitial lung disease.

5. Oxygen-dependent medical condition.

6. Any concurrent chemotherapy, investigational product (IMP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (eg, hormone replacement therapy) is acceptable.

7. Prior thoracic radiotherapy within the past 5 years before the first dose of study drug.

8. Major surgery (as defined by the Investigator) within 4 weeks prior to enrollment into the study; patients must have recovered from effects of any major surgery. Note: Local non-major surgery for palliative intent is acceptable.

9. Active or prior documented autoimmune or inflammatory disorders ( including diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener's syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion:

- Patients with vitiligo or alopecia

- Patients with hypothyroidism (e.g., following Hashimoto's disease) stable on hormone replacement

- Any chronic skin condition that does not require systemic therapy

- Patients without active disease in the last 5 years may be included but only after consultation with the study physician.

10. Active, uncontrolled inflammatory bowel disease [e.g. ulcerative colitis or Crohn's disease]. Patients in stable remission for more than 1 year may be included.

11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, interstitial lung disease, gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

12. History of another primary malignancy except for:

- Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of IMP and of low potential risk for recurrence

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease


Primary outcome:

1. Toxicity (pneumonitis) (Time Frame - up to 35 months):
Toxicity, defined by the occurence of treatment-related pneumonitis grade ≥ 3

2. Objective response (Time Frame - up to 35 months):
Objective response evaluated at 12 weeks (3 months) after first durvalumab administration according to RECIST 1.1 criteria

Secondary outcome:

1. treatment-related AEs and SAEs (Time Frame - up to 35 months):
Occurence of treatment-related AEs and SAEs according to CTCAE V5.0

2. frequency of abnormal laboratory parameters (hematology panel, chemistry panel, Thyroid-stimulating hormone (TSH)) (Time Frame - up to 35 months):
Frequency of abnormal values of laboratory parameters

3. Progression Free Survival (PFS) (Time Frame - up to 35 months):
PFS according to RECIST 1.1

4. Duration of Clinical Benefit (Time Frame - up to 35 months):
Duration of Clinical Benefit (Duration of Complete Response (CR), Partial Response (PR), Stable Disease (SD)) according to RECIST 1.1

5. Metastasis-Free Survival (MFS) (Time Frame - up to 35 months):
Time from the date of allocation / randomization to the date of first observed metastatic lesion (investigator assessment according to RECIST 1.1) or death from any cause

6. Overall survival (Time Frame - up to 35 months):
time from the date of treatment allocation to the date of death

7. Quality of Life (FACT-L) (Time Frame - up to 35 months):
measured by FACT-L questionnaire

8. objective response rate (Time Frame - up to 35 months):
Descriptive sub-group analyses of efficacy in relation to PD-L1 expression levels (<°1% vs ≥°1%)


  • Experimental: Arm A (HYPO group)
    Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles Thoracic radiation therapy (TRT): hypofractionated thoracic radiotherapy consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks (+9 days)
  • Active Comparator: Arm B (CON group)
    Durvalumab at a fixed dose of 1,500 mg as an IV infusion over 1 hour, on day 1, to be repeated every 4 weeks (Q4W) for a maximum of 12 cycles Thoracic radiation therapy (TRT): conventional fractions of 30 x 2 Gy (60 Gy) within 6 weeks (+9 days)

Geprüfte Regime

  • Durvalumab Injection [Imfinzi]:
    Durvalumab fixed dose of 1,500 mg
  • Thoracic Radiotherapy (TRT) conventionally:
    Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks
  • Thoracic Radiotherapy (TRT) hypofractionated:
    Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose